Table 2:
Demographics and Baseline Characteristics
| Overall | (R)-Propafenone | (S)-Propafenone | Placebo | |
|---|---|---|---|---|
|
| ||||
| N | 165 | 71 | 75 | 19 |
|
| ||||
| Age at enrollment | 63.4 [56.3, 70.2] | 61.8 [56.4, 68.5] | 64.9 [58.5, 70.7] | 56.3 [50.2, 70.6] |
|
| ||||
| Male | 96 (58.2%) | 38 (53.5%) | 46 (61.3%) | 12 (63.2%) |
|
| ||||
| Race | ||||
| White | 160 (97%) | 70 (98.6%) | 72 (96%) | 18 (94.7%) |
| Black | 3 (1.8%) | 1 (1.4%) | 2 (2.7%) | 0 (0%) |
| Asian | 2 (1.2%) | 0 (0%) | 1 (1.3%) | 1 (5.3%) |
| Other | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
|
| ||||
| BMI (kg/m2) | 30.1 [26.9, 34.4] | 29.3 [26.1, 33.2] | 30.4 [27.4, 35.7] | 29.6 [26.2, 35.7] |
|
| ||||
| Hypertension | 117 (70.9%) | 51 (71.8%) | 55 (73.3%) | 11 (57.9%) |
|
| ||||
| CAD | 24 (14.5%) | 11 (15.5%) | 11 (14.7%) | 2 (10.5%) |
|
| ||||
| Diabetes mellitus | 19 (11.5%) | 8 (11.3%) | 11 (14.7%) | 0 (0%) |
|
| ||||
| OSA | 41 (24.8%) | 21 (29.6%) | 18 (24%) | 2 (10.5%) |
|
| ||||
| CHF | 9 (5.5%) | 3 (4.2%) | 6 (8%) | 0 (0%) |
|
| ||||
| LVEF | ||||
| ≥50% | 164 (994%) | 70 (98.6%) | 75 (100%) | 19 (100%) |
| 40-49% | 1 (0.6%) | 1 (1.4%) | 0 (0%) | 0 (0%) |
|
| ||||
| Pacemaker/ICD | 7 (4.2%) | 2 (2.8%) | 4 (5.3%) | 1 (5.3%) |
|
| ||||
| Age at AF diagnosis | 60.0 [51.4, 66.4] | 59.2 [51.1, 65.2] | 61.3 [54.2, 67.0] | 51.5 [46.6, 68.9] |
|
| ||||
| Type of AF | ||||
| Paroxysmal | 156 (94.6%) | 63 (88.7%) | 75 (100%) | 18 (94.7%) |
| Persistent | 9 (5.4%) | 8 (11.3%) | 0 (0%) | 1 (5.3%) |
|
| ||||
| AV nodal blocker† | 116 (70%) | 44 (62%) | 48 (64%) | 14 (74%) |
|
| ||||
| Prior Class I | 83 (50.3%) | 33 (46.5%) | 40 (53.3%) | 10 (52.6%) |
|
| ||||
| Prior atrial flutter | 48 (29.1%) | 19 (26.8%) | 23 (30.7%) | 6 (31.6%) |
|
| ||||
| Prior CTI ablation | 11 (6.7%) | 5 (7.0%) | 4 (5.3%) | 2 (10.5%) |
*
Medians [IQR], N (%);
†
Includes beta-blockers and non-DHP calcium channel blockers used at the time of EP study.